Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of ImmunoCellular Therapeutics, Ltd., (Nasdaq: IMUC) violated state or federal laws. 

On December 11, 2013 after the market closed ImmunoCellular announced that its lead brain cancer drug, ICT-107, did not increase overall survival in patients diagnosed with glioblastoma multiforme. The drug did show a statistically significant benefit to patients in terms of progression-free survival, delaying the disease's progression by two months.

ImmunoCellular shares are down over 60% in early morning trading on the announcement, trading as low as $.98 per share.  However, certain officers and directors, including the founder and Chairman, sold their personally held shares at prices as high as $3.86 per shares before this news was released.

Johnson & Weaver’s investigation will seek to determine if investors were previously misled by ImmunoCellular’s officers or directors concerning ICT-107’s potential.

If you have information that could assist in this investigation, or if you are a ImmunoCellular shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-230-0063, Ext. 118.

Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com.

Johnson & Weaver, LLPJim Baker, 619-230-0063 Ext. 118jimb@johnsonandweaver.com

EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more EOM Pharmaceutical (PK) Charts.
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more EOM Pharmaceutical (PK) Charts.